|
1
|
Tunali I, Stringfield O, Guvenis A, Wang
H, Liu Y, Balagurunathan Y, Lambin P, Gillies RJ and Schabath MB:
Radial gradient and radial deviation radiomic features from
pre-surgical CT scans are associated with survival among lung
adenocarcinoma patients. Oncotarget. 8:96013–96026. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Domagala-Kulawik J and Raniszewska A: How
to evaluate the immune status of lung cancer patients before
immunotherapy. Breathe. 13:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu-Welliver M and Carbone DP: Blood-based
biomarkers in lung cancer: Prognosis and treatment decisions.
Transl Lung Cancer Res. 6:708–712. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torigoe H, Soh J, Tomida S, Namba K, Sato
H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, et al:
Induction chemoradiotherapy using docetaxel and cisplatin with
definitive-dose radiation followed by surgery for locally advanced
non-small cell lung cancer. J Thorac Dis. 9:3076–3086. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim ST, Kyung EJ, Suh JS, Lee HS, Lee JH,
Chae SI, Park ES, Chung YH, Bae J, Lee TJ, et al:
Phosphatidylcholine attenuated docetaxel-induced peripheral
neurotoxicity in rats. Drug Chem Toxicol. 41:476–485. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsunaga T, Saito H, Endo S, Iguchi K,
Soda M, El-Kabbani O, Hara A and Ikari A: Roles of aldo-keto
reductases 1B10 and 1C3 and ATP-binding cassette transporter in
docetaxel tolerance. Free Radic Res. 50:1296–1308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang K, Chen J, Chen D, Huang J, Feng B,
Han S, Chen Y, Song H, De W, Zhu Z, et al: Aurora A promotes
chemoresistance in hepatocelluar carcinoma by targeting
NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget.
5:12916–12935. 2014.PubMed/NCBI
|
|
9
|
Lykkesfeldt AE, Iversen BR, Jensen MB,
Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T and
Rasmussen BB: Aurora kinase A as a possible marker for endocrine
resistance in early estrogen receptor positive breast cancer. Acta
Oncol. 57:67–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee DH, Kim CG, Lim Y and Shin SY: Aurora
kinase A inhibitor TCS7010 demonstrates pro-apoptotic effect
through the unfolded protein response pathway in HCT116 colon
cancer cells. Oncol Lett. 14:6571–6577. 2017.PubMed/NCBI
|
|
11
|
Tagal V, Wei S, Zhang W, Brekken RA,
Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, et
al: SMARCA4-inactivating mutations increase sensitivity to Aurora
kinase A inhibitor VX-680 in non-small cell lung cancers. Nat
Commun. 8:140982017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rui W, Bing F, Hai-Zhu S, Wei D and
Long-Bang C: Identification of microRNA profiles in
docetaxel-resistant human non-small cell lung carcinoma cells
(SPC-A1). J Cell Mol Med. 14:206–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao F, Qiu H, Cui H, Ni X, Li J, Liao W,
Lu L and Ding K: MicroRNA-885-3p inhibits the growth of HT-29 colon
cancer cell xenografts by disrupting angiogenesis via targeting
BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene. 34:1968–1978.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Summerer I, Niyazi M, Unger K, Pitea A,
Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger
H: Changes in circulating microRNAs after radiochemotherapy in head
and neck cancer patients. Radiat Oncol. 8:2962013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bury L, Coelho PA, Simeone A, Ferries S,
Eyers CE, Eyers PA, Zernicka-Goetz M and Glover DM: Plk4 and Aurora
A cooperate in the initiation of acentriolar spindle assembly in
mammalian oocytes. J Cell Boil. 216:3571–3590. 2017. View Article : Google Scholar
|
|
16
|
Martin D, Fallaha S, Proctor M, Stevenson
A, Perrin L, McMillan N and Gabrielli B: Inhibition of Aurora A and
Aurora B is required for the sensitivity of HPV-Driven cervical
cancers to Aurora kinase inhibitors. Mol Cancer Ther. 16:1934–1941.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simpson PV, Casari I, Paternoster S,
Skelton BW, Falasca M and Massi M: Defining the anti-cancer
activity of tricarbonyl rhenium complexes: Induction of G2/M cell
cycle arrest and blockade of Aurora A kinase phosphorylation.
Chemistry. 23:6518–6521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asteriti IA, De Mattia F and Guarguaglini
G: Cross-talk between AURKA and Plk1 in mitotic entry and spindle
assembly. Front Oncol. 5:2832015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vo TT, Park JH, Seo JH, Lee EJ, Choi H,
Bae SJ, Le H, An S, Lee HS, Wee HJ, et al: ARD1-mediated aurora
kinase A acetylation promotes cell proliferation and migration.
Oncotarget. 8:57216–57230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alcaraz-Sanabria A, Nieto-Jimenez C,
Corrales-Sanchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC,
Burgos M, Llopis J, Galán-Moya EM, Pandiella A, et al: Synthetic
lethality interaction between aurora kinases and CHEK1 inhibitors
in ovarian cancer. Mol Cancer Ther. 16:2552–2562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiao W, Guo B, Zhou H, Xu W, Chen Y, Liang
Y and Dong B: miR-124 suppresses glioblastoma growth and
potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys
Res Commun. 486:43–48. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mesic A, Markocic E, Rogar M, Juvan R,
Hudler P and Komel R: Single nucleotide polymorphisms rs911160 in
AURKA and rs2289590 in AURKB mitotic checkpoint genes
contribute to gastric cancer susceptibility. Environ Mol Mutagen.
58:701–711. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu Y, Liu Y, Jiang J, Xi Z, Zhong N, Shi
S, Wang J and Wei X: Knocking down the expression of Aurora A gene
inhibits cell proliferation and induces G2/M phase arrest in human
small cell lung cancer cells. Oncol Rep. 32:243–249. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kozyreva VK, Kiseleva AA, Ice RJ, Jones
BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH,
Salkeni MA, et al: Combination of eribulin and Aurora A inhibitor
MLN8237 prevents metastatic colonization and induces cytotoxic
autophagy in breast cancer. Mol Cancer Ther. 15:1809–1822. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maimaiti Y, Jie T, Jing Z, Changwen W, Pan
Y, Chen C and Tao H: Aurora kinase A induces papillary thyroid
cancer lymph node metastasis by promoting cofilin-1 activity.
Biochem Biophys Res Commun. 473:212–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun JM, Yang LN, Xu H, Chang B, Wang HY
and Yang G: Inhibition of Aurora A promotes chemosensitivity via
inducing cell cycle arrest and apoptosis in cervical cancer cells.
Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI
|
|
27
|
De Bacco F, D'Ambrosio A, Casanova E,
Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL,
Luraghi P, et al: MET inhibition overcomes radiation resistance of
glioblastoma stem-like cells. EMBO Mol Med. 8:550–568. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhat P, Kriel J, Shubha Priya B, Basappa,
Shivananju NS and Loos B: Modulating autophagy in cancer therapy:
Advancements and challenges for cancer cell death sensitization.
Biochem Pharmacol. 147:170–182. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caliskan M, Guler H and Bozok Cetintas V:
Current updates on microRNAs as regulators of chemoresistance.
Biomed Pharmacother. 95:1000–1012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bourguignon LY, Earle C and Shiina M:
Activation of matrix hyaluronan-mediated CD44 signaling, epigenetic
regulation and chemoresistance in head and neck cancer stem cells.
Int J Mol Sci. 18:E18492017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang Y, Chuang AY and Ratovitski EA:
Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death
upon cisplatin exposure. Cell Cycle. 10:3938–3947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lo UG, Lee CF, Lee MS and Hsieh JT: The
role and mechanism of epithelial-to-mesenchymal transition in
prostate cancer progression. Int J Mol Sci. 18:E20792017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964.
2017.PubMed/NCBI
|
|
34
|
D'Assoro AB, Liu T, Quatraro C, Amato A,
Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, et
al: The mitotic kinase Aurora - a promotes distant metastases by
inducing epithelial-to-mesenchymal transition in ERalpha(+) breast
cancer cells. Oncogene. 33:599–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cui S, Zhang K, Li C, Chen J, Pan Y, Feng
B, Lu L, Zhu Z, Wang R and Chen L: Methylation-associated silencing
of microRNA-129-3p promotes epithelial-mesenchymal transition,
invasion and metastasis of hepatocelluar cancer by targeting Aurora
A. Oncotarget. 7:78009–78028. 2016. View Article : Google Scholar : PubMed/NCBI
|
